BMJ investigation raises concerns over 'cozy relationship' between the FDA and ... trends now
An investigation has raised concerns about the 'cozy relationship' between the Food and Drug Association (FDA) and Moderna during the Covid pandemic.
The report published in the British Medical Journal (BMJ) found two top FDA officials in charge of approving Covid vaccines left to join the pharma giant and received six-figure salaries just months after the shots got the green light.
The BMJ investigation by Dr Peter Doshi, University of Maryland pharmacy professor, warned about the lack of safeguards to prevent the 'revolving door culture' that can create 'at least the appearance of conflicts of interest'.
Technically FDA employees are supposed to wait one year before lobbying or having 'any communication to or appearance before any officer or employee of their former agency on behalf of anyone seeking official action.'
But the BMJ probe found that because the FDA keeps no record of where employees go, Dr Doran Fink and Dr Jaya Goswami slipped through the cracks.
Dr Doran Fink left his position in leadership at the FDA where he was instrumental in approving the Moderna covid shots before moving on to work for the company just two months later
Dr Goswami left the FDA and took at job at Moderna within the same month
Drs Fink and Goswami worked at the FDA for years as medical regulators for vaccines.
Dr Fink worked his way up to the post of lead medical officer in the FDA’s Office of Vaccines Research and Review, where he stayed until his appointment as Acting Deputy Director of the Office of Vaccines Research and Review.
At the FDA, the physician-scientist was responsible for working with vaccine manufacturers to advise them on the development of vaccines during the pandemic.
He was ultimately part of the decision to authorize the Pfizer-BioNTech and Moderna mRNA shots.
He left that role in December 2022. Just two months later, he took the six-figure job of Head of the Translational Medicine and Early Clinical Development within the department of infectious diseases at Moderna.
Meanwhile, Dr Goswami held her position as Medical Officer for the agency’s Center for Biologics Evaluation and Research from March 2020 until June 2022.
In that post she had, in her words, ‘broad oversight over vaccines and biologics clinical development’.
She was responsible for